BAX Stock Overview Through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Baxter International Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Baxter International Historical stock prices Current Share Price US$28.66 52 Week High US$40.63 52 Week Low US$27.56 Beta 0.57 1 Month Change -11.13% 3 Month Change -18.18% 1 Year Change -18.11% 3 Year Change -62.14% 5 Year Change -61.83% Change since IPO -51.60%
Recent News & Updates
Baxter International Inc. Announces Continued Growth of Pharmaceuticals Portfolio with Five Injectable Product Launches in the U.S Dec 11
Baxter International Inc. Announces Resignation of Peter M. Wilver as Board of Directors, and the Audit Committee and Compensation and Human Capital Committee, Effective December 31, 2024 Nov 23
Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2025 Nov 13
Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2025 Nov 12
Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024 Nov 08 Baxter International Inc. Provides Update on North Cove, N.C., Facility Oct 01
See more updates
Baxter International Inc. Announces Continued Growth of Pharmaceuticals Portfolio with Five Injectable Product Launches in the U.S Dec 11
Baxter International Inc. Announces Resignation of Peter M. Wilver as Board of Directors, and the Audit Committee and Compensation and Human Capital Committee, Effective December 31, 2024 Nov 23
Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2025 Nov 13
Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2025 Nov 12
Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024 Nov 08 Baxter International Inc. Provides Update on North Cove, N.C., Facility Oct 01
-Baxter International Inc. Appoints Jeffrey A. Craig to Its Board Sep 11
New minor risk - Share price stability Aug 25
Upcoming dividend of US$0.29 per share Aug 23 The Carlyle Group Inc. (NasdaqGS:CG) and Atmas Health entered into an Equity Purchase Agreement to acquire Vantive Health LLC from Baxter International Inc. (NYSE:BAX) for $3.8 billion. Aug 14
Second quarter 2024 earnings released: US$0.62 loss per share (vs US$0.39 loss in 2Q 2023) Aug 07
Baxter International Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024 Aug 07
Baxter International Inc. Announces Launch of the Helion Integrated Surgical System in Thailand Jul 30
First quarter dividend of US$0.29 announced Jul 19
Baxter International Inc. Declares Quarterly Dividend, Payable on October 1, 2024 Jul 17
Carlyle Group Reportedly in Advanced Talks to Buy Baxter's Vantive Business Jul 06
Baxter International Inc. Announces New Data Showing Expanded Hemodialysis, Known as HDX Therapy May 30
Upcoming dividend of US$0.29 per share May 24
Baxter International Inc. Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication May 14
First quarter dividend of US$0.29 announced May 09
Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2024 May 08
Baxter International Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024 May 03
First quarter 2024 earnings released: EPS: US$0.073 (vs US$0.002 loss in 1Q 2023) May 02
Baxter International Inc. Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S Apr 11
Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy Apr 03
Baxter International Inc., Annual General Meeting, May 07, 2024 Mar 26
Upcoming dividend of US$0.29 per share Feb 22
Fourth quarter dividend of US$0.29 announced Feb 15
Full year 2023 earnings released: US$0.15 loss per share (vs US$4.83 loss in FY 2022) Feb 08
Baxter International Inc. Provides Sales Guidance for the First Quarter and Full Year 2024 Feb 08
Now 22% overvalued after recent price rise Jan 26
Baxter International Inc. Announces the Completion of the First Phase of Its Intravenous (IV) Bag Recycling Program Pilot Dec 14
Upcoming dividend of US$0.29 per share at 3.2% yield Nov 23
Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2024 Nov 15
New minor risk - Share price stability Nov 13
Baxter International Inc. Highlights New Data At Kidney Week Indicating Sharesource Is Associated with A 77% Lower Risk of Home Dialysis Technique Failure Nov 07 Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Year 2023
Third quarter 2023 earnings released: EPS: US$0.095 (vs US$5.83 loss in 3Q 2022) Nov 02
Baxter International Inc. Digital Image Capture Capability for PanOptic Plus Ophthalmoscope Oct 17 Baxter International Inc. Announces Management Appointments
Levi & Korsinsky Notifies Baxter International Inc. Investors of A Class Action Lawsuit and Upcoming Deadline Sep 06
New major risk - Revenue and earnings growth Aug 24
Upcoming dividend of US$0.29 per share at 2.8% yield Aug 24
Baxter International Inc. Announces Board Changes Aug 22
The Klein Law Firm Announces That A Class Action Complaint Has Been Filed on Behalf of Shareholders of Baxter International Inc. Alleging That the Company Violated Federal Securities Laws Aug 02
Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.36 profit in 2Q 2022) Jul 28
Baxter International Inc. Launches PERCLOT Absorbable Hemostatic Powder Jul 25
Baxter International Inc. Declares Quarterly Cash Dividend, Payable on October 2, 2023 Jul 21
Rosen Law Firm Announces the Filing of Class Action Lawsuit on Behalf of Purchasers of Securities of Baxter International Inc Jul 14
High number of new directors Jul 05 Baxter International Inc. Appoints William Ampofo to Its Board of Directors Baxter International Inc.(NYSE:BAX) dropped from Russell 1000 Growth Index
Upcoming dividend of US$0.29 per share at 2.8% yield May 25 Baxter International Inc. Announces James K. Saccaro Notifies to Resign as Executive Vice President, Effective as of May 31, 2023 Advent International Corporation and Warburg Pincus LLC signed a definitive agreement to acquire Baxter Pharmaceutical Solutions LLC from Baxter International Inc. (NYSE:BAX) for $4.3 billion.
Baxter International Inc. Selects Chris Toth to Be Chief Executive Officer of the Company’s Planned Spinoff of Its Renal Care and Acute Therapies Businesses May 06
First quarter 2023 earnings released: EPS: US$0.087 (vs US$0.14 in 1Q 2022) Apr 29
Baxter International Inc. Announces Management Changes Feb 16
Baxter International Inc. Declares Quarterly Dividend, Payable on April 3, 2023 Feb 15
Full year 2022 earnings released: US$4.83 loss per share (vs US$2.56 profit in FY 2021) Feb 10 Baxter International Inc. Reports Goodwill Impairment for the Fourth Quarter Ended December 31, 2022
Baxter International Inc. Announces Resignation of Giuseppe Accogli as Executive Vice President and Chief Operating Officer Jan 07
Baxter Introduces ExactaMix Pro Automated Compounder Dec 02
Upcoming dividend of US$0.29 per share Nov 24
Baxter International Inc. Declares Quarterly Cash Dividend, Payable on January 3, 2023 Nov 16
Baxter International Inc. Highlights New Home Dialysis and HDX Therapy Data in 14 Clinical Presentations At Kidney Week 2022 Nov 08
Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022 Oct 28
Third quarter 2022 earnings released: US$5.83 loss per share (vs US$0.90 profit in 3Q 2021) Oct 27
Baxter International Inc. to Report Q3, 2022 Results on Oct 27, 2022 Sep 08
Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software Sep 01
Upcoming dividend of US$0.29 per share Aug 25
Second quarter 2022 earnings released: EPS: US$0.25 (vs US$0.59 in 2Q 2021) Jul 29
Baxter International Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022 Jul 29
Baxter International Inc. Announces Executive Changes Jul 21
Baxter International Inc. Declares Quarterly Dividend, Payable on October 3, 2022 Jul 13
Upcoming dividend of US$0.29 per share May 26
Baxter International Inc. Announces Board Changes May 09
Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2022 May 04
First quarter 2022 earnings released: EPS: US$0.14 (vs US$0.59 in 1Q 2021) Apr 29
Baxter International Inc. Announces Findings of an Observational Study on Data from the Starling Registry Apr 20
Baxter Announces U.S. FDA Clearance of ST Set Used to Help Treat Acute Kidney Injury Patients in the Hospital Apr 06
Baxter International Inc., Annual General Meeting, May 03, 2022 Mar 23
Baxter International Inc. Presents Data Indicating Sharesource Increases Patients’ Time on Home Dialysis by More Than Three Months Mar 03 Shareholder Returns BAX AT Medical Equipment AT Market 7D 0.7% -1.8% -0.8% 1Y -18.1% 5.4% -1.6%
See full shareholder returns
Return vs Market: BAX underperformed the Austrian Market which returned -1.6% over the past year.
Price Volatility Is BAX's price volatile compared to industry and market? BAX volatility BAX Average Weekly Movement 3.6% Medical Equipment Industry Average Movement 6.1% Market Average Movement 3.8% 10% most volatile stocks in AT Market 6.3% 10% least volatile stocks in AT Market 2.1%
Stable Share Price: BAX has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: BAX's weekly volatility (4%) has been stable over the past year.
About the Company Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
Show more Baxter International Inc. Fundamentals Summary How do Baxter International's earnings and revenue compare to its market cap? BAX fundamental statistics Market cap €14.44b Earnings (TTM ) €115.97m Revenue (TTM ) €14.44b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BAX income statement (TTM ) Revenue US$15.06b Cost of Revenue US$9.42b Gross Profit US$5.64b Other Expenses US$5.52b Earnings US$121.00m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 0.24 Gross Margin 37.47% Net Profit Margin 0.80% Debt/Equity Ratio 162.9%
How did BAX perform over the long term?
See historical performance and comparison Dividends
2.3% Current Dividend Yield When do you need to buy BAX by to receive an upcoming dividend? Baxter International dividend dates Ex Dividend Date Nov 29 2024 Dividend Pay Date Jan 02 2025 Days until Ex dividend 24 days Days until Dividend pay date 10 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 06:10 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Baxter International Inc. is covered by 46 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jasper Hellweg Argus Research Company Benjamin Yeoh Atlantic Equities LLP Daniel Owczarski Avondale Partners
Show 43 more analysts 
